US 11,376,274 B2 · Joint cavity injection preparation and use thereof

Abstract

A joint cavity injection preparation is provided. The active ingredient of the joint cavity injection preparation is deacetylated xanthan gum (XG). The deacetylated XG has a molecular weight of 500,000 to 20,000,000. The joint cavity injection preparation is prepared from deacetylated xanthan gum (XG), which has higher biocompatibility and safe wide-dosage range than existing joint cavity injection preparations prepared from XG.

Claims12

Dependent claims

A joint cavity injection preparation, wherein

an active ingredient of the joint cavity injection preparation is deacetylated xanthan gum (XG);
the deacetylated XG has a molecular weight of 5,000,000 to 10,000,000;
and
a percentage of a mass of the deacetylated XG in a volume of the joint cavity injection preparation is 3% to 5% (w/v);
wherein the joint cavity injection preparation further comprises disodium phosphate (DSP) and monosodium phosphate (MSP).

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/297,467Filed 21 May 2019

Priority

CN 201811455378.530 Nov 2018

Published

US 2021/0353662 A118 Nov 2021

Granted

5 Jul 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/723
Glucans: xanthans
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/7016
Carbohydrates; Sugars; Derivatives thereof: disaccharides, e.g. lactose, lactulose
A61K 31/722
Glucans: chitin, chitosan

Joint cavity injection preparation and use thereof

Life of this patent

Joint cavity injection preparation and use thereof

Life of this patent

Abstract

Claims12